Oct 23, 2025 7:30 AM Eastern Daylight Time Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma Share No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toug ...